glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Role of Inhibitors in Clinical Practice Comparison of GLP-1 receptor agonists

Hsia DS, Grove O, Cefalu WT

Trulicity is a once-weekly injection thats approved by the Food and Drug Administration (FDA) to control blood sugar in people 10 and older with Type 2 diabetes and to reduce the risk of heart attack, stroke, and cardiovascular death in adults with both Type 2 diabetes and cardiovascular disease (or multiple risk factors)

The Institute for Clinical and Economic Review deemed GLP-1s lacking in cost effectiveness for obesity management in 2022

Also GLP1RAs have been found to decrease epicardial fat, which may help explain their potential in lowering the risk of atherosclerosis

The fact that I made the 7-37 peptide at Mass General, where the clinical studies were done, turned out to be critical

Although these findings offer reassurance regarding the safety of these drugs, further validation is essential